Keyphrases
Combination Therapy
100%
Pemafibrate
100%
Dapagliflozin
100%
Metabolic-associated Fatty Liver Disease (MAFLD)
100%
Obesity
40%
Body Weight Reduction
40%
Older Men
20%
Peroxisome Proliferator-activated Receptor
20%
Therapeutic Strategies
20%
Proteinuria
20%
Metabolic Syndrome
20%
Type 1 Diabetes Mellitus (T1DM)
20%
Nephrotic Syndrome
20%
Hyperglycemia
20%
Hepatic Injury
20%
Receptor Modulators
20%
Disease Syndrome
20%
Optimal Medical Therapy
20%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
20%
Diabetic Dyslipidemia
20%
Hypertriglyceridemia
20%
Obesity Body Mass Index
20%
Focal Segmental Glomerulosclerosis
20%
Medical Strategy
20%
Medicine and Dentistry
Combination Therapy
100%
Non-Alcoholic Fatty Liver Disease
100%
Pemafibrate
100%
Dapagliflozin
100%
Body Weight
40%
Diabetes Mellitus
20%
Body Mass Index
20%
Peroxisome Proliferator Activated Receptor
20%
Metabolic Syndrome
20%
Proteinuria
20%
Nephrotic Syndrome
20%
Hyperglycemia
20%
Hypertriglyceridemia
20%
Liver Injury
20%
Dyslipidemia
20%
Sodium Glucose Cotransporter 2 Inhibitor
20%
Focal Segmental Glomerulosclerosis
20%
Pharmacology, Toxicology and Pharmaceutical Science
Fatty Liver
100%
Combination Therapy
100%
Pemafibrate
100%
Dapagliflozin
100%
Diabetes Mellitus
20%
Metabolic Syndrome X
20%
Peroxisome Proliferator Activated Receptor
20%
Hyperglycemia
20%
Liver Injury
20%
Proteinuria
20%
Dyslipidemia
20%
Hypertriglyceridemia
20%
Sodium Glucose Cotransporter 2 Inhibitor
20%
Nephrotic Syndrome
20%
Focal Glomerulosclerosis
20%